Latest News

See All Latest News Right Pointing Arrow
Woman in chemo trial
HOPA Members

The Many Layers of BIPOC Underrepresentation in Cancer Clinical Trials

November 06, 2024

HOPA member Veronica B. Ajewole, PharmD, BCOP, brings her perspective on how to increase participation of Black, Indigenous, and People of Color (BIPOC) patients in cancer clinical trials.

Advocacy

HOPA and CMRignite Launch "Time to Talk Diversity in Clinical Trials" Campaign

November 04, 2024

HOPA and CMRignite have collaborated on "Time to Talk Diversity in Clinical Trials," a campaign to address the critical need for increased diversity in cancer clinical research and ensure that all patient populations are adequately represented.

Image of stem cell treatment
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Axatilimab-csfr

October 14, 2024

Sydney Hunt, PharmD, PGY-1 Pharmacist Resident, and Lindsay Orton, PharmD, BCOP, Stem Cell Transplant and Cellular Therapy Clinical Pharmacist, both from Vanderbilt University Medical Center, Nashville, TN, write about axatilimab-csfr (Niktimvo).

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Afamitresgene autoleucel

October 09, 2024

Emili Anderson, PharmD, PGY1 Acute Care Resident, and Roger Ngo, PharmD Candidate, both from UNC Medical Center, Chapel Hill, NC, write about afamitresgene autoleucel (afami-cel).

digital medical illustration of lung cancer in a person's chest
Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Tarlatamab-dlle

September 26, 2024

SeongEun Emily Park, PharmD PGY2-Hematology/Oncology Pharmacy Resident Emory University Hospital Midtown/Winship Cancer Institute writes about tarlatamab-dlle.

red blood cells under a microscope with signs of cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: imetelstat

September 24, 2024

Brian Lam, PharmD, PGY2 Oncology Pharmacy Resident at University of North Carolina, Chapel Hill, NC writes about imetelstat

Explore more from HOPA

-positive non-small cell lung cancer
Drug Updates

Pharmacist’s Application to Practice: Repotrectinib

January 25, 2024

Christopher L. Cornett II, PharmD PGY1 Acute Care Pharmacy Resident Anne E Hitron, PharmD, MS, MBA, BCOP ,Oncology Pharmacy Specialist, Baptist Health Louisville, Louisville, Kentucky

Metastatic Colorectal Cancer
Journal Club

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

May 04, 2024

The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously

Visual of data being collected
Late Breaking News

Oncology Pharmacy Staffing Survey Across Practice Settings in the United States

September 19, 2024

The results of a recently published pharmacy staffing model survey has brought new insights into oncology pharmacy operations across the country.

uveal melanoma with unresectable hepatic metastases
Drug Updates

Pharmacist’s Application to Practice: Hepzato Kit™

January 11, 2024

Lainey Vargo, PharmD, PGY2-Oncology Resident Katie Murto, PharmD, BCOP and Crystal Heise, PharmD, BCOP WVUH Hospitals, Morgantown, West Virginia.

Journal Club

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

October 23, 2023

Amivantamab–chemotherapy improved PFS and intracranial PFS versus chemotherapy.

Late Breaking News

Clinical Oncology Pharmacy Technician: Impact of a New Role on Pharmacy and Patient Metrics at a Large Academic Cancer Center

September 20, 2024

A recently published article details the impact of having an inpatient clinical oncology pharmacy technician program.

Myelofibrosis with anemia
Drug Updates

Pharmacist's Application to Practice: Momelotinib

January 11, 2024

Diana Mansour, PharmD, BCOP, Clinical Pharmacy Specialist, Charles M Gallagher, PharmD, PGY2 Oncology Pharmacy Resident; Kelsea Seago, PharmD, BCOP, Clinical Pharmacy Specialist, allfrom WVUH Hospitals, write about Momelotinib.

metastatic non-small cell lung cancer
Journal Club

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 23, 2023

First-line treatment with osimertinib–chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC.

Early-Stage Non-small Cell Lung Cancer
Late Breaking News

Late-Breaking HOPA News: Adjuvant Alectinib in Early-Stage Non-small Cell Lung Cancer (NSCLC)

June 12, 2024

In April 2024, the FDA approved alectinib (Alecensa®) in patients with early-stage ALK-positive non-small cell lung cancer (NSCLC) based on the ALINA trial.